person · Reporting owner

STARR CHRISTOPHER M

Disclosed activity across 2 companies

Tapewire entity: 72059
SEC CIK: 0001235470

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Monopar TherapeuticsMNPR · Entity 5152	Director	October 01, 2026	October 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Monopar Therapeutics

Report date October 01, 2026 · Filed October 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,173	Ending reported balance After 2026-10-01 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-10-01 · Exercise / conversion · Acquired 8,400 · Balance 13,573 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. Row 2 · 2026-10-01 · Sale · Disposed 4,631 · Balance 8,942 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Row 3 · 2026-10-01 · Sale · Disposed 2,970 · Balance 5,972 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Row 4 · 2026-10-01 · Sale · Disposed 799 · Balance 5,173 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2027-02-19	Direct	8,400	Reported balance After 2026-10-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-10-01 · Exercise / conversion · Disposed 8,400 · Balance 8,400 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F2: On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	9,880	Reported balance Holding disclosure · report date 2026-10-01 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 9,880 F3: Represents shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

F2: On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.

F3: Represents shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Raptor Pharmaceutical Corp

Report date October 24, 2016 · Filed October 26, 2016

Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2016-10-25 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2016-10-24 · Other · Disposed 706,065 · Balance 8,330 F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Row 2 · 2016-10-25 · Disposition to issuer · Disposed 8,330 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2021-09-22	Direct	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 460,064 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.49 · Expires 2022-09-25	Direct	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.

F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.

F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2026 Filed Oct 5, 2026 21:43 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionStock Option · Derivative	8,400	$0.00 Strike: $0.01	$0.00	Disclosure SEC source: 0001437749-26-032048 · rdgdoc.xml · derivative · entry 6 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 8,400 shares Expires 2027-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F2 · derivative.exercise_date: On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter. Read SEC document
October 01, 2026 Filed Oct 5, 2026 21:43 UTC	Monopar Therapeutics MNPR · Entity 5152	SaleCommon Stock	799	$79.67	$63,656.33	Disclosure SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 4 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,173 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Read SEC document
October 01, 2026 Filed Oct 5, 2026 21:43 UTC	Monopar Therapeutics MNPR · Entity 5152	SaleCommon Stock	2,970	$78.82	$234,095.40	Disclosure SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,972 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Read SEC document
October 01, 2026 Filed Oct 5, 2026 21:43 UTC	Monopar Therapeutics MNPR · Entity 5152	SaleCommon Stock	4,631	$78.09	$361,634.79	Disclosure SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 2 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,942 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. Read SEC document
October 01, 2026 Filed Oct 5, 2026 21:43 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	8,400	$0.01	$42.00	Disclosure SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026. Read SEC document
December 02, 2025 Filed Dec 8, 2025 16:50 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantStock Options · Derivative	2,924	$0.00 Strike: $75.94	$0.00	Disclosure SEC source: 0001437749-25-037170 · rdgdoc.xml · derivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,924 Underlying: Common Stock · 2,924 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026. Read SEC document
July 14, 2025 Filed Jul 16, 2025 21:03 UTC	Monopar Therapeutics MNPR · Entity 5152	OtherStock Options · Derivative	16,800	$0.00 Strike: $0.01	$0.00	Disclosure SEC source: 0001437749-25-022862 · rdgdoc.xml · derivative · entry 4 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,800 shares Expires 2026-04-04 F4 · derivative.exercise_date: Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Starr on April 4, 2016, for his services as a director of Monopar Therapeutics. The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter. Read SEC document
July 14, 2025 Filed Jul 16, 2025 21:03 UTC	Monopar Therapeutics MNPR · Entity 5152	SaleCommon Stock	16,800	$40.00	$672,020.16	Disclosure SEC source: 0001437749-25-022862 · rdgdoc.xml · nonDerivative · entry 2 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,173 F2 · price: The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 14, 2025 Filed Jul 16, 2025 21:03 UTC	Monopar Therapeutics MNPR · Entity 5152	OtherCommon Stock	16,800	$0.01	$84.00	Disclosure SEC source: 0001437749-25-022862 · rdgdoc.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,973 F1 · shares: This transaction involved a cash exercise of stock options. Read SEC document
March 04, 2025 Filed Mar 7, 2025 20:14 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantStock Options · Derivative	11,365	$0.00 Strike: $31.70	$0.00	Disclosure SEC source: 0001437749-25-006730 · rdgdoc.xml · derivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,365 Underlying: Common Stock · 11,365 shares Expires 2035-03-04 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. Read SEC document
December 31, 2023 Filed Jan 3, 2024 19:37 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,533	$0.00	$0.00	Disclosure SEC source: 0001437749-24-000483 · rdgdoc.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
December 31, 2023 Filed Jan 3, 2024 19:37 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,533	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-24-000483 · rdgdoc.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
September 30, 2023 Filed Oct 3, 2023 19:35 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,533	$0.00	$0.00	Disclosure SEC source: 0001437749-23-027586 · rdgdoc.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,533 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
September 30, 2023 Filed Oct 3, 2023 19:35 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,533	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-027586 · rdgdoc.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
June 30, 2023 Filed Jul 3, 2023 18:46 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,534	$0.00	$0.00	Disclosure SEC source: 0001437749-23-019259 · rdgdoc.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,066 Underlying: Common Stock · 2,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
June 30, 2023 Filed Jul 3, 2023 18:46 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,534	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-019259 · rdgdoc.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
March 31, 2023 Filed Apr 4, 2023 17:21 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,533	$0.00	$0.00	Disclosure SEC source: 0001437749-23-009337 · rdgdoc.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
March 31, 2023 Filed Apr 4, 2023 17:21 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,533	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-009337 · rdgdoc.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
February 01, 2023 Filed Feb 3, 2023 18:43 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantRestricted Stock Units · Derivative	10,133	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001437749-23-002514 · rdgdoc.xml · derivative · entry 2 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,133 Underlying: Common Stock · 10,133 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document
February 01, 2023 Filed Feb 3, 2023 18:43 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantStock Options · Derivative	13,930	$0.00 Strike: $3.16	$0.00	Disclosure SEC source: 0001437749-23-002514 · rdgdoc.xml · derivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,930 Underlying: Common Stock · 13,930 shares Expires 2033-02-01 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document
December 31, 2022 Filed Jan 3, 2023 16:08 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,859	$0.00	$0.00	Disclosure SEC source: 0001437749-23-000170 · rdgdoc.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
December 31, 2022 Filed Jan 3, 2023 16:08 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,859	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-000170 · rdgdoc.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
September 30, 2022 Filed Oct 3, 2022 19:57 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,859	$0.00	$0.00	Disclosure SEC source: 0001654954-22-013281 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
September 30, 2022 Filed Oct 3, 2022 19:57 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,859	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-013281 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
June 30, 2022 Filed Jul 1, 2022 16:06 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,859	$0.00	$0.00	Disclosure SEC source: 0001654954-22-009137 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,718 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
June 30, 2022 Filed Jul 1, 2022 16:06 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,859	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-009137 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
March 31, 2022 Filed Apr 1, 2022 17:02 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	2,859	$0.00	$0.00	Disclosure SEC source: 0001654954-22-004480 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
March 31, 2022 Filed Apr 1, 2022 17:02 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	2,859	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-004480 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
February 02, 2022 Filed Feb 4, 2022 19:35 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantRestricted Stock Options · Derivative	11,436	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001654954-22-001171 · section16.xml · derivative · entry 2 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,436 Underlying: Common Stock · 11,436 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document
February 02, 2022 Filed Feb 4, 2022 19:35 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantStock Options · Derivative	15,128	$0.00 Strike: $2.80	$0.00	Disclosure SEC source: 0001654954-22-001171 · section16.xml · derivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,128 Underlying: Common Stock · 15,128 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document
December 31, 2021 Filed Jan 4, 2022 13:20 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	751	$0.00	$0.00	Disclosure SEC source: 0001654954-22-000118 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
December 31, 2021 Filed Jan 4, 2022 13:20 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	751	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-000118 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
September 30, 2021 Filed Oct 1, 2021 19:28 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	751	$0.00	$0.00	Disclosure SEC source: 0001654954-21-010718 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
September 30, 2021 Filed Oct 1, 2021 19:28 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	751	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-010718 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
June 30, 2021 Filed Jul 2, 2021 17:18 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	752	$0.00	$0.00	Disclosure SEC source: 0001654954-21-007605 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,502 Underlying: Common Stock · 752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
June 30, 2021 Filed Jul 2, 2021 17:18 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	752	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-007605 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
March 31, 2021 Filed Apr 1, 2021 19:49 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	751	$0.00	$0.00	Disclosure SEC source: 0001654954-21-003796 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,254 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
March 31, 2021 Filed Apr 1, 2021 19:49 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	751	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-003796 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
January 26, 2021 Filed Jan 28, 2021 18:54 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantRestricted Stock Units · Derivative	3,005	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001654954-21-000917 · section16.xml · derivative · entry 2 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Underlying: Common Stock · 3,005 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document
January 26, 2021 Filed Jan 28, 2021 18:54 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantStock Options · Derivative	4,443	$0.00 Strike: $6.81	$0.00	Disclosure SEC source: 0001654954-21-000917 · section16.xml · derivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Underlying: Common Stock · 4,443 shares Expires 2031-01-25 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document
December 31, 2020 Filed Jan 5, 2021 17:36 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	322	$0.00	$0.00	Disclosure SEC source: 0001654954-21-000154 · section16.xml · derivative · entry 5 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
December 31, 2020 Filed Jan 5, 2021 17:36 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	322	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-000154 · section16.xml · nonDerivative · entry 2 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
September 30, 2020 Filed Jan 5, 2021 17:36 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	322	$0.00	$0.00	Disclosure SEC source: 0001654954-21-000154 · section16.xml · derivative · entry 4 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
September 30, 2020 Filed Jan 5, 2021 17:36 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	322	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-000154 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:36 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	323	$0.00	$0.00	Disclosure SEC source: 0001654954-20-007303 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644 Underlying: Common Stock · 323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:36 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	323	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-20-007303 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
March 31, 2020 Filed Apr 1, 2020 14:38 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionRestricted Stock Units · Derivative	322	$0.00	$0.00	Disclosure SEC source: 0001654954-20-003677 · section16.xml · derivative · entry 3 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document
March 31, 2020 Filed Apr 1, 2020 14:38 UTC	Monopar Therapeutics MNPR · Entity 5152	Exercise / conversionCommon Stock	322	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-20-003677 · section16.xml · nonDerivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document
January 31, 2020 Filed Feb 20, 2020 21:00 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantStock Options · Derivative	5,646	$0.00 Strike: $14.35	$0.00	Disclosure SEC source: 0001654954-20-001795 · section16.xml · derivative · entry 2 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,646 Underlying: Common Stock · 5,646 shares Expires 2030-01-31 F2 · derivative.exercise_date: Stock options vest 25% on March 31, 2020, 25% on June 30, 2020, 25% on September 30, 2020, and 25% on December 31, 2020. Read SEC document
January 31, 2020 Filed Feb 20, 2020 21:00 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantRestricted Stock Units · Derivative	1,289	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001654954-20-001795 · section16.xml · derivative · entry 1 STARR CHRISTOPHER M · CIK 0001235470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289 Underlying: Common Stock · 1,289 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 25% on April 1, 2020, 25% on July 1, 2020, 25% on October 1, 2020, and 25% on January 1, 2021. F1 · derivative.expiration_date: Restricted stock units vest 25% on April 1, 2020, 25% on July 1, 2020, 25% on October 1, 2020, and 25% on January 1, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.